Skip to main content
CADL
NASDAQ Life Sciences

Director Paul Manning Buys Nearly $3M in Candel Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$5.689
Mkt Cap
$282.726M
52W Low
$4.25
52W High
$9.209
52W Position info
34% above low
Off High info
38% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

CADL sits 34% above its 52-week low of $4.25.

Summary

Director Paul B. Manning made a significant open market purchase of Candel Therapeutics common stock, investing nearly $3 million.


Key Events · Ownership and Investor Activity · CADL

  • Significant Insider Purchase

    Director Paul B. Manning acquired 550,458 shares of Candel Therapeutics common stock in an open market transaction on February 23, 2026, at a price of $5.45 per share.

  • Substantial Investment

    The purchase totaled $2,999,996, representing over 1% of the company's current market capitalization.

  • Follows Recent Capital Raises

    This insider buying occurs shortly after the company secured a $100 million public offering and a $100 million royalty funding agreement, bolstering its financial runway.


Analysis · CADL · Life Sciences

This significant purchase by a director, representing over 1% of the company's market capitalization, signals strong conviction in the company's future. It closely follows the company's recent $100 million public offering and a $100 million royalty funding agreement, both of which substantially strengthened Candel Therapeutics' financial position. This insider buying could be interpreted as a vote of confidence in the company's strategic direction and its ability to execute on its plans with the newly secured capital.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CADL was trading at $5.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $282.7M. The 52-week trading range was $4.25 to $9.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Sep 09, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.14
Real-time Price: $10.40 info
Change: -$1.74 (-14%) info
Market Cap: $806.888M info
CADL
Aug 13, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.56
Real-time Price: $10.40 info
Change: -$0.160 (-2%) info
Market Cap: $806.888M info
CADL
Aug 13, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.56
Real-time Price: $10.40 info
Change: -$0.160 (-2%) info
Market Cap: $806.888M info
CADL
Jun 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.43
Real-time Price: $10.40 info
Change: -$0.034 (-0.33%) info
Market Cap: $806.888M info
CADL
Jun 02, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.80
Real-time Price: $10.40 info
Change: +$1.60 (+18%) info
Market Cap: $806.888M info